Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neoadjuvant Chemotherapy Response in Triple-Negative Apocrine Carcinoma: Comparing Apocrine Morphology, Androgen Receptor, and Immune Phenotypes.

Archives of pathology & laboratory medicine - 1 Apr 2025

Hwang Inwoo, Lim Yoojoo, Song Sanghoon, Lee Hyunwoo, Cho Yoon Ah, Im Young-Hyuck, An Jin Seok, Park Yeon Hee, Kim Ji-Yeon, Cho Eun Yoon

Abstract excerpt

CONTEXT.—: Apocrine differentiation and androgen receptor (AR) positivity represent a specific subset of triple-negative breast cancer (TNBC) and are often considered potential prognostic or predictive factors. OBJECTIVE.—: To evaluate the response of TNBC to neoadjuvant chemotherapy (NAC) and to assess the impact of apocrine morphology, AR status, Ki-67 labeling index (Ki-67LI), and tumor-infiltrating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ki-67 Antigen

Share to Lymphocytes, Tumor-Infiltrating

Share to Neoadjuvant Therapy

Share to Phenotype

Share to Receptors, Androgen

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 38960391
DOI: 10.5858/arpa.2023-0561-OA

Genes

AR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neoadjuvant Chemotherapy Response in Triple-Negative Apocrine Carcinoma: Comparing Apocrine Morphology, Androgen Receptor, and Immune Phenotypes.PMID 38960391Read ↗

Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.Semantic proximity Read ↗

Triple Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant ChemotherapySemantic proximity Read ↗

The development of Breast Apocrine Carcinoma (BAC) score that distinguishes breast and cutaneous apocrine carcinomasSemantic proximity Read ↗

Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.Semantic proximity Read ↗

Proteogenomic Characterization of Triple-Negative Apocrine Carcinoma Reveals Molecular Features of Progression and Chemotherapy ResponseSemantic proximity Read ↗

Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.Semantic proximity Read ↗

HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and OutcomeSemantic proximity Read ↗

Classification of breast tumours into molecular apocrine, luminal and basal groups based on an explicit biological modelSemantic proximity Read ↗

Assessing the Androgen Receptor Status in Clinicopathologic and Hematologic Characteristics of the Triple-negative Breast CancerSemantic proximity Read ↗

Stromal Tumor-Infiltrating Lymphocytes Are Associated with Immune Checkpoint Protein Expression in Triple-Negative Breast Cancer Patients: A Subset of the Karachi PopulationSemantic proximity Read ↗

Identification of molecular apocrine breast tumours by microarray analysis.Semantic proximity Read ↗

Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.